AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
AbbVie Inc. has announced layoffs affecting approximately 300 employees as part of a restructuring effort. The layoffs are set to take place in North Chicago, Illinois, and come amidst significant changes in the company's leadership, including the departure of its Chief Financial Officer. This decision reflects AbbVie's ongoing adjustments to streamline operations and adapt to market conditions. The company has not specified which departments will be impacted by these layoffs, but they are part of a broader strategy to enhance efficiency. The layoffs are expected to be completed by the end of the month.
AbbVie Inc. has laid off approximately 50 scientists following its decision to terminate a partnership with a Google-backed longevity company. The layoffs occurred in the company's Research and Development department located in North Chicago, Illinois. This move reflects AbbVie's strategic shift away from certain projects in the longevity sector. The company has not disclosed further details about the future of its research initiatives or any additional workforce adjustments. The layoffs are part of a broader reevaluation of AbbVie's business strategies in response to changing market conditions.
AbbVie Inc. has laid off over 100 employees following the termination of its 11-year partnership with Calico. This decision reflects a strategic shift as AbbVie moves away from its collaboration with the biotech company. The layoffs are part of AbbVie's efforts to streamline operations and focus on its core business areas. The exact location of the layoffs has not been specified, but the impact is significant as the company adjusts its workforce in light of the recent changes. This move underscores the ongoing evolution within the pharmaceutical industry as companies reassess their partnerships and operational strategies.
AbbVie Inc.'s subsidiary, Allergan, has laid off over 200 employees following a failed marketing campaign. The decision comes as part of a restructuring effort to realign the company's focus and resources. The layoffs are indicative of the challenges faced by Allergan in effectively promoting its products. While specific locations and departments affected were not disclosed, the cuts reflect a significant adjustment in workforce strategy. This move is part of AbbVie's broader efforts to streamline operations and enhance efficiency in a competitive market.
AbbVie has announced plans to reduce its workforce by approximately 1,000 employees across its US operations. This decision comes as part of a broader strategy to streamline operations and improve efficiency in response to changing market conditions. The layoffs are expected to impact various departments, although specific details on locations and departments affected have not been disclosed. AbbVie aims to implement these changes in the coming months to better position itself for future growth and sustainability.
AbbVie has announced plans to lay off 85 employees at its Allergan unit located in California. These layoffs are scheduled for the summer, as part of a restructuring effort within the company. The decision reflects AbbVie's ongoing adjustments to its workforce in response to market conditions and operational needs. The layoffs are expected to impact various roles within the Allergan division, although specific details on the affected positions have not been disclosed. This move highlights AbbVie's strategic focus on optimizing its operations amid changing industry dynamics.
No one has shared a story from AbbVie Inc. yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.